Ann: Change in substantial holding, page-5

Coincidentally, FebriDx will have it's 10th birthday at that time. Like most ten year olds, it also hasn't generated revenue and has been scolded by the authorities.

From the Cash Flow Report issued yesterday:

1) "Lumos recorded unaudited revenue of $2.0 million for the quarter...."

2) "Lumos generated $1.9 million from the provision of diagnostic test development services and contract
manufacturing during the March quarter...."

3) "Orders for FebriDx from distributors in four European markets remained relatively modest but are
starting to gain momentum."

4) "ViraDx is currently under review by the US FDA for Emergency Use Authorization (EUA)."

and 5) "Cash usage for the quarter of $3.2 million, average of $1.1 million per month"

Why is there talk of either product turning this company around? $2MM - $1.9MM = $100,000 over 3 months. At best FebriDx is generating $34k a month and their burn is 32x that!

Can someone tell me why they are wasting OUR investments on regulatory expenses when other companies are discontinuing their covid related products and there are multiple covid/flu products already on the market?